Celcuity/$CELC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Ticker
$CELC
Sector
Primary listing
Employees
87
Headquarters
Website
Celcuity Metrics
BasicAdvanced
$2.3B
-
-$3.45
0.68
-
Price and volume
Market cap
$2.3B
Beta
0.68
52-week high
$55.44
52-week low
$7.58
Average daily volume
2.2M
Financial strength
Current ratio
4.584
Quick ratio
4.216
Long term debt to equity
223.721
Total debt to equity
224.034
Interest coverage (TTM)
-11.27%
Profitability
EBITDA (TTM)
-146.486
Management effectiveness
Return on assets (TTM)
-38.50%
Return on equity (TTM)
-134.54%
Valuation
Price to book
47.88
Price to tangible book (TTM)
47.88
Price to free cash flow (TTM)
-19.521
Free cash flow yield (TTM)
-5.12%
Free cash flow per share (TTM)
-2.797
Growth
Earnings per share change (TTM)
28.56%
3-year earnings per share growth (CAGR)
18.83%
What the Analysts think about Celcuity
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Celcuity Financial Performance
Revenues and expenses
Celcuity Earnings Performance
Company profitability
Celcuity News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celcuity stock?
Celcuity (CELC) has a market cap of $2.3B as of August 30, 2025.
What is the P/E ratio for Celcuity stock?
The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of August 30, 2025.
Does Celcuity stock pay dividends?
No, Celcuity (CELC) stock does not pay dividends to its shareholders as of August 30, 2025.
When is the next Celcuity dividend payment date?
Celcuity (CELC) stock does not pay dividends to its shareholders.
What is the beta indicator for Celcuity?
Celcuity (CELC) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.